XL-114

N/A

Report date: 2026/04/18 20:00:19

Base Information

Drug NameXL-114
Drug Alias NameXL-114AUR-104
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitorsCaspase recruitment domain-containing protein 11 inhibitorsB-cell lymphoma/leukemia 10 inhibitors
TargetsMucosa-associated lymphoid tissue lymphoma translocation protein 1Caspase recruitment domain-containing protein 11B-cell lymphoma/leukemia 10
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAurigene Discovery Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAurigene Discovery Technologies LtdExelixis Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[6] 

Other Information

ATC CodeN/A
Related LinksN/A